<p>Cwm LLC 在最近提交給證券交易委員會（SEC）的 13F 文件中表示，在第二季度將其在 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免費報告）中的持股比例提高了 46.4%。該機構投資者在本季度額外購買了 27,894 股後，持有該生物技術公司 87,955 股股票。Cwm LLC 在 BioMarin Pharmaceutical 的持股在最近的報告期末價值為 4,835,000 美元。</p>
<ul>
<li>BioMarin 股票能否滿足華爾街的高期望？</li>
</ul>
<p>其他機構投資者最近也對該公司的持股進行了調整。V Square Quantitative Management LLC 在第二季度購買了 BioMarin Pharmaceutical 的新股份，價值 25,000 美元。Farther Finance Advisors LLC 在第一季度將其在 BioMarin Pharmaceutical 的持股增加了 95.9%。Farther Finance Advisors LLC 目前持有 431 股該生物技術公司的股票，價值 29,000 美元，此前在上個季度額外購買了 211 股。Rise Advisors LLC 在第一季度購買了 BioMarin Pharmaceutical 的新股份，價值 30,000 美元。Brooklyn Investment Group 在第一季度將其在 BioMarin Pharmaceutical 的持股增加了 2,250.0%。Brooklyn Investment Group 目前持有 564 股該生物技術公司的股票，價值 40,000 美元，此前在上個季度額外購買了 540 股。最後，Banque Transatlantique SA 在第一季度購買了 BioMarin Pharmaceutical 的新股份，價值 71,000 美元。機構投資者持有該公司 98.71% 的股票。</p>
<h2>華爾街分析師的看法</h2>
<p>BMRN 最近成為幾份分析師報告的主題。瑞銀集團將 BioMarin Pharmaceutical 的目標價格從 113.00 美元上調至 114.00 美元，並在 8 月 5 日的研究報告中給予該股票 “買入” 評級。摩根士丹利將 BioMarin Pharmaceutical 的目標價格從 97.00 美元下調至 96.00 美元，並在 7 月 22 日的報告中對該股票給予 “增持” 評級。古根海姆將 BioMarin Pharmaceutical 的目標價格從 101.00 美元上調至 106.00 美元，並在 8 月 6 日的報告中給予該股票 “買入” 評級。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 BioMarin Pharmaceutical 的 “賣出（d+）” 評級。最後，Zacks Research 在 8 月 13 日的報告中將 BioMarin Pharmaceutical 的評級從 “強力買入” 下調至 “持有”。十三位研究分析師對該股票給予了買入評級，八位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 93.26 美元。</p>
<ul>
<li>3 只超賣股票具有大幅 RSI 反彈潛力</li>
</ul>
<p><strong>查看我們對 BMRN 的最新分析</strong></p>
<h2>BioMarin Pharmaceutical 價格表現</h2>
<p>BMRN 週五開盤價為 52.95 美元。該公司的市值為 101.7 億美元，市盈率為 15.71，PEG 比率為 0.67，貝塔值為 0.33。該公司的速動比率為 3.60，流動比率為 5.56，債務股本比率為 0.10。該公司的 50 日移動平均價格為 55.74 美元，200 日移動平均價格為 57.67 美元。BioMarin Pharmaceutical Inc. 的 12 個月低點為 51.56 美元，12 個月高點為 73.51 美元。</p>
<h2>BioMarin Pharmaceutical 公司簡介</h2>
<p>（免費報告）</p>
<ul>
<li>基因治療股票會成為市場下一個大贏家嗎？</li>
</ul>
<p>BioMarin Pharmaceutical Inc. 開發和商業化針對嚴重和危及生命的罕見疾病及醫療狀況的治療方案。其商業產品包括 Vimizim，一種用於治療粘多糖貯積症（MPS）IV 型 A 的酶替代療法；Naglazyme，一種用於 MPS VI 患者的重組 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一種用於治療苯丙酮尿症（PKU）患者的專有合成口服形式 6R-BH4，這是一種遺傳代謝疾病。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 BioMarin Pharmaceutical</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>Salesforce 期待已久的拐點來了：繼續上漲！</li>
<li>3 只值得長期持有的 REITs</li>
<li>Rocket Lab USA 獲得華爾街的認可：是時候買入了嗎？</li>
<li>什麼是成長股及其投資方式</li>
<li>Archer 在戰略舉措中收購競爭對手的專利寶藏</li>
</ul>
<p><strong>想看看其他對 BMRN 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 BioMarin Pharmaceutical 嗎？</h2>
<p>在考慮 BioMarin Pharmaceutical 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在買入，以便在更廣泛的市場注意到之前……而 BioMarin Pharmaceutical 並不在名單上。</p>
<p>雖然 BioMarin Pharmaceutical 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

拜瑪林制藥

<p>Cwm LLC 在第二季度將其在拜瑪林製藥（NASDAQ:BMRN）的持股增加了 46.4%，額外購買了 27,894 股，使其總持股達到 87,955 股，價值為 483 萬美元。其他機構投資者也調整了他們的持倉。分析師對 BMRN 的評級不一，目標價格範圍在 93.26 美元到 114.00 美元之間。該股票開盤價為 52.95 美元，市值為 101.7 億美元，12 個月的價格區間為 51.56 美元到 73.51 美元。拜瑪林專注於罕見疾病的治療</p>

<p>Cwm LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 46.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,955 shares of the biotechnology company's stock after acquiring an additional 27,894 shares during the quarter. Cwm LLC's holdings in BioMarin Pharmaceutical were worth $4,835,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Cwm LLC 在最近提交給證券交易委員會（SEC）的 13F 文件中表示，在第二季度將其在 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免費報告）中的持股比例提高了 46.4%。該機構投資者在本季度額外購買了 27,894 股後，持有該生物技術公司 87,955 股股票。Cwm LLC 在 BioMarin Pharmaceutical 的持股在最近的報告期末價值為 4,835,000 美元。</p>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>BioMarin 股票能否滿足華爾街的高期望？</li>
</ul>
</div><p>Other institutional investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth $25,000. Farther Finance Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 211 shares in the last quarter. Rise Advisors LLC bought a new stake in shares of BioMarin Pharmaceutical in the 1st quarter worth $30,000. Brooklyn Investment Group grew its stake in shares of BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 540 shares in the last quarter. Finally, Banque Transatlantique SA bought a new stake in shares of BioMarin Pharmaceutical in the 1st quarter worth $71,000. Institutional investors own 98.71% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者最近也對該公司的持股進行了調整。V Square Quantitative Management LLC 在第二季度購買了 BioMarin Pharmaceutical 的新股份，價值 25,000 美元。Farther Finance Advisors LLC 在第一季度將其在 BioMarin Pharmaceutical 的持股增加了 95.9%。Farther Finance Advisors LLC 目前持有 431 股該生物技術公司的股票，價值 29,000 美元，此前在上個季度額外購買了 211 股。Rise Advisors LLC 在第一季度購買了 BioMarin Pharmaceutical 的新股份，價值 30,000 美元。Brooklyn Investment Group 在第一季度將其在 BioMarin Pharmaceutical 的持股增加了 2,250.0%。Brooklyn Investment Group 目前持有 564 股該生物技術公司的股票，價值 40,000 美元，此前在上個季度額外購買了 540 股。最後，Banque Transatlantique SA 在第一季度購買了 BioMarin Pharmaceutical 的新股份，價值 71,000 美元。機構投資者持有該公司 98.71% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>BMRN has been the subject of several recent analyst reports. UBS Group upped their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, August 5th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, July 22nd. Guggenheim boosted their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, August 6th. Weiss Ratings reissued a &#34;sell (d+)&#34; rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of BioMarin Pharmaceutical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, August 13th. Thirteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $93.26.</p>
<div class="lb-trans"><p>BMRN 最近成為幾份分析師報告的主題。瑞銀集團將 BioMarin Pharmaceutical 的目標價格從 113.00 美元上調至 114.00 美元，並在 8 月 5 日的研究報告中給予該股票 “買入” 評級。摩根士丹利將 BioMarin Pharmaceutical 的目標價格從 97.00 美元下調至 96.00 美元，並在 7 月 22 日的報告中對該股票給予 “增持” 評級。古根海姆將 BioMarin Pharmaceutical 的目標價格從 101.00 美元上調至 106.00 美元，並在 8 月 6 日的報告中給予該股票 “買入” 評級。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 BioMarin Pharmaceutical 的 “賣出（d+）” 評級。最後，Zacks Research 在 8 月 13 日的報告中將 BioMarin Pharmaceutical 的評級從 “強力買入” 下調至 “持有”。十三位研究分析師對該股票給予了買入評級，八位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 93.26 美元。</p>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超賣股票具有大幅 RSI 反彈潛力</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on BMRN</strong></p>
<div class="lb-trans"><p><strong>查看我們對 BMRN 的最新分析</strong></p>
</div><h2>BioMarin Pharmaceutical Price Performance</h2>
<div class="lb-trans"><h2>BioMarin Pharmaceutical 價格表現</h2>
</div><p>BMRN opened at $52.95 on Friday. The company has a market capitalization of $10.17 billion, a price-to-earnings ratio of 15.71, a PEG ratio of 0.67 and a beta of 0.33. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $55.74 and a 200-day moving average price of $57.67. BioMarin Pharmaceutical Inc. has a twelve month low of $51.56 and a twelve month high of $73.51.</p>
<div class="lb-trans"><p>BMRN 週五開盤價為 52.95 美元。該公司的市值為 101.7 億美元，市盈率為 15.71，PEG 比率為 0.67，貝塔值為 0.33。該公司的速動比率為 3.60，流動比率為 5.56，債務股本比率為 0.10。該公司的 50 日移動平均價格為 55.74 美元，200 日移動平均價格為 57.67 美元。BioMarin Pharmaceutical Inc. 的 12 個月低點為 51.56 美元，12 個月高點為 73.51 美元。</p>
</div><h2>BioMarin Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>BioMarin Pharmaceutical 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治療股票會成為市場下一個大贏家嗎？</li>
</ul>
</div><p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p>
<div class="lb-trans"><p>BioMarin Pharmaceutical Inc. 開發和商業化針對嚴重和危及生命的罕見疾病及醫療狀況的治療方案。其商業產品包括 Vimizim，一種用於治療粘多糖貯積症（MPS）IV 型 A 的酶替代療法；Naglazyme，一種用於 MPS VI 患者的重組 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一種用於治療苯丙酮尿症（PKU）患者的專有合成口服形式 6R-BH4，這是一種遺傳代謝疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than BioMarin Pharmaceutical</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 BioMarin Pharmaceutical</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>Salesforce 期待已久的拐點來了：繼續上漲！</li>
<li>3 只值得長期持有的 REITs</li>
<li>Rocket Lab USA 獲得華爾街的認可：是時候買入了嗎？</li>
<li>什麼是成長股及其投資方式</li>
<li>Archer 在戰略舉措中收購競爭對手的專利寶藏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMRN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 BMRN 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=BMRN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 BioMarin Pharmaceutical 嗎？</h2>
</div><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 BioMarin Pharmaceutical 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在買入，以便在更廣泛的市場注意到之前……而 BioMarin Pharmaceutical 並不在名單上。</p>
</div><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 BioMarin Pharmaceutical 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cwm LLC 購買了 27,894 股拜瑪林製藥公司的股票，股票代碼為$BMRN